Cardiff Oncology (CRDF) Competitors $2.43 -0.01 (-0.41%) Closing price 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDF vs. MGTX, DAWN, AUTL, KALV, AVBP, DNTH, VIR, ANAB, TSHA, and ORGOShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include MeiraGTx (MGTX), Day One Biopharmaceuticals (DAWN), Autolus Therapeutics (AUTL), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Dianthus Therapeutics (DNTH), Vir Biotechnology (VIR), AnaptysBio (ANAB), Taysha Gene Therapies (TSHA), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Cardiff Oncology vs. Its Competitors MeiraGTx Day One Biopharmaceuticals Autolus Therapeutics KalVista Pharmaceuticals ArriVent BioPharma Dianthus Therapeutics Vir Biotechnology AnaptysBio Taysha Gene Therapies Organogenesis Cardiff Oncology (NASDAQ:CRDF) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Is CRDF or MGTX more profitable? MeiraGTx has a net margin of -415.39% compared to Cardiff Oncology's net margin of -9,344.14%. Cardiff Oncology's return on equity of -77.94% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-9,344.14% -77.94% -63.65% MeiraGTx -415.39%-239.38%-59.35% Does the media refer more to CRDF or MGTX? In the previous week, MeiraGTx had 9 more articles in the media than Cardiff Oncology. MarketBeat recorded 10 mentions for MeiraGTx and 1 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.87 beat MeiraGTx's score of 0.56 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Overall Sentiment Cardiff Oncology Very Positive MeiraGTx Positive Do analysts rate CRDF or MGTX? Cardiff Oncology presently has a consensus target price of $10.10, suggesting a potential upside of 315.64%. MeiraGTx has a consensus target price of $24.00, suggesting a potential upside of 201.13%. Given Cardiff Oncology's higher probable upside, equities research analysts clearly believe Cardiff Oncology is more favorable than MeiraGTx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, CRDF or MGTX? Cardiff Oncology has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Which has better valuation and earnings, CRDF or MGTX? Cardiff Oncology has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$680K237.75-$45.43M-$0.87-2.79MeiraGTx$33.28M19.24-$147.79M-$2.04-3.91 Do institutionals and insiders hold more shares of CRDF or MGTX? 16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 7.7% of Cardiff Oncology shares are held by insiders. Comparatively, 7.5% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryCardiff Oncology beats MeiraGTx on 10 of the 16 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDF vs. The Competition Export to ExcelMetricCardiff OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.67M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-2.7920.7630.8625.25Price / Sales237.75231.85403.9088.50Price / CashN/A41.5625.2228.45Price / Book1.319.759.516.00Net Income-$45.43M-$54.74M$3.26B$265.34M7 Day Performance4.29%8.09%4.49%2.81%1 Month Performance-43.22%7.70%5.18%1.50%1 Year Performance1.67%18.13%31.98%25.46% Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDFCardiff Oncology1.9535 of 5 stars$2.43-0.4%$10.10+315.6%+2.1%$161.67M$680K-2.7920MGTXMeiraGTx4.479 of 5 stars$7.84-0.5%$24.00+206.1%+93.1%$633.28M$33.28M-3.38300News CoverageEarnings ReportAnalyst ForecastDAWNDay One Biopharmaceuticals2.4202 of 5 stars$5.90-3.3%$25.33+329.4%-51.5%$624.84M$131.16M-6.2160Positive NewsAUTLAutolus Therapeutics3.0247 of 5 stars$2.47+6.0%$9.32+277.3%-52.5%$620.11M$10.12M-2.81330News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionKALVKalVista Pharmaceuticals4.0715 of 5 stars$12.51+0.8%$26.29+110.1%+7.3%$619.93MN/A-3.39100AVBPArriVent BioPharma2.218 of 5 stars$17.42-3.2%$39.29+125.5%-19.8%$615.48MN/A-4.6240Earnings ReportAnalyst RevisionHigh Trading VolumeDNTHDianthus Therapeutics1.5175 of 5 stars$18.89+0.7%$53.00+180.6%-27.9%$603.32M$6.24M-5.8180News CoverageAnalyst RevisionVIRVir Biotechnology3.5611 of 5 stars$4.28-0.5%$30.25+606.8%-47.6%$597.34M$74.21M-1.07580Positive NewsANABAnaptysBio3.1284 of 5 stars$20.00-4.9%$47.75+138.8%-40.8%$588.78M$91.28M-4.46100TSHATaysha Gene Therapies3.4726 of 5 stars$2.76+1.5%$8.17+195.9%+30.7%$583.88M$8.33M-8.12180Earnings ReportAnalyst RevisionORGOOrganogenesis4.2426 of 5 stars$4.61+1.3%$7.50+62.7%+84.8%$577.84M$482.04M-32.93950 Related Companies and Tools Related Companies MGTX Competitors DAWN Competitors AUTL Competitors KALV Competitors AVBP Competitors DNTH Competitors VIR Competitors ANAB Competitors TSHA Competitors ORGO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDF) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access